Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $26.60.

Several brokerages have weighed in on ATXS. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Wedbush reiterated an “outperform” rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, JMP Securities started coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $4.66 on Friday. Astria Therapeutics has a 52-week low of $4.62 and a 52-week high of $12.92. The firm has a market capitalization of $262.98 million, a PE ratio of -2.23 and a beta of 0.68. The stock has a fifty day simple moving average of $6.58 and a two-hundred day simple moving average of $8.95.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. On average, sell-side analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in Astria Therapeutics during the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC increased its holdings in Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Astria Therapeutics during the fourth quarter worth $50,000. Virtus ETF Advisers LLC purchased a new position in Astria Therapeutics during the fourth quarter valued at $65,000. Finally, Quest Partners LLC grew its position in shares of Astria Therapeutics by 180.8% in the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.